Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 3
Submit an article Journal homepage
192
Views
0
CrossRef citations to date
0
Altmetric
Review

Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers

David B Page1 Melanoma/Sarcoma Service, Memorial Sloan-Kettering Cancer Center, NY, USA;2 Columbia University Medical Center, New York-Presbyterian Hospital, NY, USA
,
Jianda Yuan3 Ludwig Center for Cancer Immunotherapy, Sloan-Kettering Institute, NY, USA; 1275York Avenue, Box #340, NY10065, USA
&
Jedd D Wolchok1 Melanoma/Sarcoma Service, Memorial Sloan-Kettering Cancer Center, NY, USA;3 Ludwig Center for Cancer Immunotherapy, Sloan-Kettering Institute, NY, USA; 1275York Avenue, Box #340, NY10065, USACorrespondence[email protected]
Pages 367-379 | Published online: 10 May 2010

Bibliography

  • Shankaran V , IkedaH, BruceATet al.: IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity.Nature410(6832) , 1107–1111 (2001).
  • Dunn GP , KoebelCM, SchreiberRD: Interferons, immunity and cancer immunoediting.Nat. Rev. Immunol.6(11) , 836–848 (2006).
  • Dunn GP , OldLJ, SchreiberRD: The three Es of cancer immunoediting.Annu. Rev. Immunol.22 , 329–360 (2004).
  • Dunn GP , OldLJ, SchreiberRD: The immunobiology of cancer immunosurveillance and immunoediting.Immunity21(2) , 137–148 (2004).
  • Hanahan D , WeinbergRA: The hallmarks of cancer.Cell100(1) , 57–70 (2000).
  • Leach DR , KrummelMF, AllisonJP: Enhancement of antitumor immunity by CTLA-4 blockade.Science271(5256) , 1734–1736 (1996).
  • Ribas A , CamachoLH, Lopez-BeresteinGet al.: Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.J. Clin. Oncol.23(35) , 8968–8977 (2005).
  • Attia P , PhanGQ, MakerAVet al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.J. Clin. Oncol.23(25) , 6043–6053 (2005).
  • Maker AV , PhanGQ, AttiaPet al.: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study.Ann. Surg. Oncol.12(12) , 1005–1016 (2005).
  • Movva S , VerschraegenC: The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.Expert Opin. Biol. Ther.9(2) , 231–241 (2009).
  • Downey SG , KlapperJA, SmithFOet al.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.Clin. Cancer Res.13(22 Pt 1) , 6681–6688 (2007).
  • Peggs KS , QuezadaSA, KormanAJ, AllisonJP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.Curr. Opin. Immunol.18(2) , 206–213 (2006).
  • O‘Day S , WeberJ, LebbeCet al.: Effect of ipilimumab treatment on 18-month survival: update of patients (pts) with advanced melanoma treated with 10mg/kg ipilimumab in three Phase II clinical trials. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Middleton MR , GrobJJ, AaronsonNet al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.J. Clin. Oncol.18(1) , 158–166 (2000).
  • Yuan J , PageDB, KuGYet al.: Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.Cancer Immun10 , 1 (2010).
  • Saenger YM , WolchokJD: The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.Cancer Immun8 , 1 (2008).
  • Wolchok JD , SaengerY: The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.Oncologist13(Suppl. 4) , 2–9 (2008).
  • van der Merwe PA , DavisSJ: Molecular interactions mediating T cell antigen recognition.Annu. Rev. Immunol.21 , 659–684 (2003).
  • Krummel MF , AllisonJP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J. Exp. Med.182(2) , 459–465 (1995).
  • Egen JG , KuhnsMS, AllisonJP: CTLA-4: new insights into its biological function and use in tumor immunotherapy.Nat. Immunol.3(7) , 611–618 (2002).
  • Wing K , OnishiY, Prieto-MartinPet al.: CTLA-4 control over Foxp3+ regulatory T cell function.Science322(5899) , 271–275 (2008).
  • Peggs KS , QuezadaSA, ChambersCA, KormanAJ, AllisonJP: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.J. Exp. Med.206(8) , 1717–1725 (2009).
  • Quezada SA , PeggsKS, CurranMA, AllisonJP: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.J. Clin. Invest.116(7) , 1935–1945 (2006).
  • Kavanagh B , O‘BrienS, LeeDet al.: CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.Blood112(4) , 1175–1183 (2008).
  • Houghton AN , EisingerM, AlbinoAP, CairncrossJG, OldLJ: Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.J. Exp. Med.156(6) , 1755–1766 (1982).
  • Chen YT , ScanlanMJ, SahinUet al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.Proc. Natl Acad. Sci. USA94(5) , 1914–1918 (1997).
  • Nakada T , NoguchiY, SatohSet al.: NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.Cancer Immun.3 , 10 (2003).
  • Perales MA , BlachereNE, EngelhornMEet al.: Strategies to overcome immune ignorance and tolerance.Semin. Cancer Biol.12(1) , 63–71 (2002).
  • Gnjatic S , YuanJ, RitterEet al.: Serum antibodies as predictive markers of clinical response to anti-CTLA-4 (ipimilumab) treatment in advanced melanoma patients. Presented at: ASCO 2008 Annual Meeting. Chicago, IL, USA, 30 May–3 June 2008.
  • Fong L , KwekSS, O‘BrienSet al.: Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.Cancer Res.69(2) , 609–615 (2009).
  • Fong L , SmallEJ: Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.J. Clin. Oncol.26(32) , 5275–5283 (2008).
  • Paschen A , SuckerA, HillBet al.: Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.Clin. Cancer Res.15(16) , 5208–5215 (2009).
  • Jinushi M , HodiFS, DranoffG: Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.Proc. Natl Acad. Sci. USA103(24) , 9190–9195 (2006).
  • Contardi E , PalmisanoGL, TazzariPLet al.: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction.Int. J. Cancer117(4) , 538–550 (2005).
  • Bruggemann M , WilliamsGT, BindonCIet al.: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.J. Exp. Med.166(5) , 1351–1361 (1987).
  • Cranmer LD , HershE: The role of the CTLA4 blockade in the treatment of malignant melanoma.Cancer Invest.25(7) , 613–631 (2007).
  • Khong HT , RestifoNP: Natural selection of tumor variants in the generation of ‘tumor escape‘ phenotypes.Nat. Immunol.3(11) , 999–1005 (2002).
  • Wolchok JD , NeynsB, LinetteGet al.: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study.Lancet Oncol.11(2) , 155–164 (2009).
  • Beck KE , BlansfieldJA, TranKQet al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.J. Clin. Oncol.24(15) , 2283–2289 (2006).
  • Weber J : Ipilimumab: controversies in its development, utility and autoimmune adverse events.Cancer Immunol. Immunother.58(5) , 823–830 (2009).
  • Sanderson K , ScotlandR, LeePet al.: Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma.J. Clin. Oncol.23(4) , 741–750 (2005).
  • Blansfield JA , BeckKE, TranKet al.: Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.J. Immunother.28(6) , 593–598 (2005).
  • Lutzky J , WolchokJ, HamidOet al.: Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10mg/kg ipilimumab in three Phase II clinical trials. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Amin A , de Pril V, Hamid O et al.: Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Ribas A : Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).Oncologist13(Suppl. 4) , 10–15 (2008).
  • Ribas A , HauschildA, KeffordRet al.: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. Presented at: ASCO 2008 Annual Meeting. Chicago, IL, USA, 30 May–3 June 2008.
  • Weber JS , SarnaikA, TarganSet al.: Phase II trial of extended dose anti-CTLA4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. Presented at: ASCO 2008 Annual Meeting. Chicago, IL, USA, 30 May–3 June 2008.
  • Wolchok JD , de Pril V, Linette G et al.: Efficacy of ipilimumab 10mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Kwon ED , HurwitzAA, FosterBAet al.: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.Proc. Natl Acad. Sci. USA94(15) , 8099–8103 (1997).
  • Hurwitz AA , FosterBA, KwonEDet al.: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.Cancer Res.60(9) , 2444–2448 (2000).
  • Gregor PD , WolchokJD, FerroneCRet al.: CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.Vaccine22(13–14) , 1700–1708 (2004).
  • van Elsas A , HurwitzAA, AllisonJP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.J. Exp. Med.190(3) , 355–366 (1999).
  • Phan GQ , YangJC, SherryRMet al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.Proc. Natl Acad. Sci. USA100(14) , 8372–8377 (2003).
  • Pierret L , WilgenhofS, CorthalsJ, RoelandtT, ThielemansK, NeynsB: Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated with ipilimumab. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Ribas A , Comin-AnduixB, ChmielowskiBet al.: Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.Clin. Cancer Res.15(19) , 6267–6276 (2009).
  • Mohebtash M , MadanRA, ArienMet al.: Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Mokyr MB , KalinichenkoT, GorelikL, BluestoneJA: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.Cancer Res.58(23) , 5301–5304 (1998).
  • Demaria S , KawashimaN, YangAMet al.: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.Clin. Cancer Res.11(2 Pt 1) , 728–734 (2005).
  • Hersh E , WeberJ, PowderlyJet al.: Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Slovin SF , BeerTM, HiganoSet al.: Initial Phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Dong H , StromeSE, SalomaoDRet al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat. Med.8(8) , 793–800 (2002).
  • Sarnaik AA , WeberJS: Recent advances using anti-CTLA-4 for the treatment of melanoma.Cancer J.15(3) , 169–173 (2009).
  • Hamid O , UrbaWJ, YellinMet al.: Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
  • Hodi FS , HoosA, IbrahimRet al.: Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. Presented at: ASCO 2008 Annual Meeting. Chicago, IL, USA, 30 May–3 June 2008.
  • Wolchok JD , HoosA, O‘DaySet al.: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.Clin. Cancer Res.15(23) , 7412–7420 (2009).
  • Berman DM , WolchokJ, WeberJ, HamidO, O‘DayS, ChasalowSD: Association of peripheral blood absolute lymphocyte count (CESAREAN) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Ku G , YuanJ, PageDet al.: Compassionate-use trial of ipilimumab in patients with advanced melanoma: lymphocyte count after two doses correlates with survival.Cancer116(7) , 1767–1775 (2010).
  • Wada H , SatoE, UenakaAet al.: Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.Int. J. Cancer123(10) , 2362–2369 (2008).
  • Yuan J , GnjaticS, LiHet al.: CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.Proc. Natl Acad. Sci. USA105(51) , 20410–20415 (2008).
  • Klein O , EbertLM, NicholaouTet al.: Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.Clin. Cancer Res.15(7) , 2507–2513 (2009).
  • Comin-Anduix B , LeeY, JalilJet al.: Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.J. Transl. Med.6 , 22 (2008).
  • Gnjatic S , WheelerC, EbnerMet al.: Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays.J. Immunol. Methods341(1–2) , 50–58 (2009).
  • Makedonas G , BettsMR: Polyfunctional analysis of human T cell responses: importance in vaccine immunogenicity and natural infection.Springer Semin. Immunopathol.28(3) , 209–219 (2006).
  • Duvall MG , PrecopioML, AmbrozakDAet al.: Polyfunctional T cell responses are a hallmark of HIV-2 infection.Eur. J. Immunol.38(2) , 350–363 (2008).
  • De Rosa SC , LuFX, YuJet al.: Vaccination in humans generates broad T cell cytokine responses.J. Immunol.173(9) , 5372–5380 (2004).
  • Precopio ML , BettsMR, ParrinoJet al.: Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses.J. Exp. Med.204(6) , 1405–1416 (2007).
  • Perales MA , YuanJ, PowelSet al.: Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.Mol. Ther.16(12) , 2022–2029 (2008).
  • Reuben JM , LeeBN, LiCet al.: Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.Cancer106(11) , 2437–2444 (2006).
  • Maker AV , AttiaP, RosenbergSA: Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.J. Immunol.175(11) , 7746–7754 (2005).
  • Menard C , GhiringhelliF, RouxSet al.: CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?Clin. Cancer Res.14(16) , 5242–5249 (2008).
  • Muranski P , BoniA, AntonyPAet al.: Tumor-specific Th17-polarized cells eradicate large established melanoma.Blood112(2) , 362–373 (2008).
  • von Euw E , ChodonT, AttarNet al.: CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.J. Transl. Med.7 , 35 (2009).
  • Liakou CI , KamatA, TangDNet al.: CTLA-4 blockade increases IFN-γ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.Proc. Natl Acad. Sci. USA105(39) , 14987–14992 (2008).
  • Hutloff A , DittrichAM, BeierKCet al.: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.Nature397(6716) , 263–266 (1999).
  • Lohning M , HutloffA, KallinichTet al.: Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10.J. Exp. Med.197(2) , 181–193 (2003).
  • Burmeister Y , LischkeT, DahlerACet al.: ICOS controls the pool size of effector-memory and regulatory T cells.J. Immunol.180(2) , 774–782 (2008).
  • Hamid O , ChasalowSD, TsuchihasiZ, AlaparthyS, GalbraithS, BermanDM: Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
  • Breunis WB , Tarazona-SantosE, ChenR, KileyM, RosenbergSA, ChanockSJ: Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.J. Immunother.31(6) , 586–590 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.